However, the best treatment for BED often involves a multimodal approach that may include psychotherapy, medication, and lifestyle changes
None of this establishes a benefit, effect or outcome in humans, and cagrilintide is not a licensed medicine
Phase 3 trials need to finish, the data needs analysis and publication, and the FDA needs to grant approval
The FAQs refer out to Chapter 4729:7-2 regarding Pharmacy Compounding, Chapter 4729:7-3 regarding Prescriber Compounding, and Chapter 4729:6-10 regarding Outsourcing Facilities for in depth requirements for compounding
Beyond obesity itself, these findings suggest future peptide therapies may address inflammation, cardiovascular risk, osteoarthritis, and broader metabolic dysfunction simultaneously